AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPT
  4. [Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

RAPT Therapeutics President and CEO Brian Russell Wong received a significant stock option grant on June 20, 2025. The derivative securities transaction involved:

  • Grant of 637,500 stock options to purchase common stock
  • Exercise price set at $7.43 per share
  • Options expire on June 19, 2035
  • Vesting schedule: 1/48th of shares vest monthly starting June 20, 2025

This Form 4 filing discloses the equity-based compensation grant to Wong, who serves as both Director and CEO. The substantial option grant, which represents direct ownership, appears to be part of the company's executive compensation strategy to align management interests with shareholders over a long-term ten-year period.

Brian Russell Wong, Presidente e CEO di RAPT Therapeutics, ha ricevuto una significativa concessione di opzioni su azioni il 20 giugno 2025. La transazione relativa a strumenti derivati comprendeva:

  • Concessione di 637.500 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Scadenza delle opzioni il 19 giugno 2035
  • Piano di maturazione: 1/48 delle azioni matura mensilmente a partire dal 20 giugno 2025

Questo deposito del Modulo 4 rende nota la concessione di compensi azionari a Wong, che ricopre sia il ruolo di Direttore che di CEO. La consistente assegnazione di opzioni, che rappresenta una propriet脿 diretta, sembra far parte della strategia di remunerazione esecutiva dell'azienda per allineare gli interessi del management con quelli degli azionisti in un periodo di lungo termine di dieci anni.

Brian Russell Wong, Presidente y CEO de RAPT Therapeutics, recibi贸 una importante concesi贸n de opciones sobre acciones el 20 de junio de 2025. La transacci贸n con valores derivados incluy贸:

  • Concesi贸n de 637,500 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $7.43 por acci贸n
  • Las opciones expiran el 19 de junio de 2035
  • Calendario de adquisici贸n: 1/48 de las acciones se adquiere mensualmente a partir del 20 de junio de 2025

Esta presentaci贸n del Formulario 4 revela la concesi贸n de compensaci贸n basada en acciones a Wong, quien es Director y CEO. La considerable concesi贸n de opciones, que representa propiedad directa, parece ser parte de la estrategia de compensaci贸n ejecutiva de la compa帽铆a para alinear los intereses de la gerencia con los de los accionistas durante un per铆odo a largo plazo de diez a帽os.

RAPT Therapeutics鞚� 靷灔 瓴� CEO鞚� Brian Russell Wong鞚� 2025雲� 6鞗� 20鞚检棎 靸侂嫻頃� 欤检嫕毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃姷雼堧嫟. 鞚� 韺岇儩靸來拡 瓯半灅電� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 甑Г頃� 靾� 鞛堧姅 637,500 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $7.43搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 19鞚�
  • 氩犾姢韺� 鞚检爼: 2025雲� 6鞗� 20鞚茧秬韯� 毵れ洈 1/48鞌� 氩犾姢韺�

鞚� Form 4 鞝滌稖靹滊姅 鞚挫偓鞚挫瀽 CEO鞚� Wong鞐愱矊 歆�旮夒悳 欤检嫕 旮半皹 氤挫儊 攵赌鞐ゼ 瓿店皽頃╇媹雼�. 歆侅爲 靻岇湢甓岇潉 雮橅儉雮措姅 靸侂嫻頃� 鞓奠厴 攵赌鞐姅 瓴届榿歆勳潣 鞚挫澋鞚� 欤检＜鞕� 鞛リ赴鞝侅溂搿� 10雲� 霃欖晥 鞚检箻鞁滍偆旮� 鞙勴暅 須岇偓鞚� 鞛勳洂 氤挫儊 鞝勲灥鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟.

Brian Russell Wong, Pr茅sident et CEO de RAPT Therapeutics, a re莽u une attribution importante d鈥檕ptions d鈥檃chat d鈥檃ctions le 20 juin 2025. La transaction concernant des titres d茅riv茅s comprenait :

  • Attribution de 637 500 options d鈥檃chat d鈥檃ctions pour acqu茅rir des actions ordinaires
  • Prix d鈥檈xercice fix茅 脿 7,43 $ par action
  • Expiration des options le 19 juin 2035
  • Calendrier d鈥檃cquisition : 1/48 des actions acquises chaque mois 脿 partir du 20 juin 2025

Ce d茅p么t du formulaire 4 r茅v猫le l鈥檃ttribution de r茅mun茅ration en actions 脿 Wong, qui est 脿 la fois administrateur et CEO. Cette importante attribution d鈥檕ptions, repr茅sentant une propri茅t茅 directe, semble faire partie de la strat茅gie de r茅mun茅ration des dirigeants de l鈥檈ntreprise visant 脿 aligner les int茅r锚ts de la direction avec ceux des actionnaires sur une p茅riode longue de dix ans.

Brian Russell Wong, Pr盲sident und CEO von RAPT Therapeutics, erhielt am 20. Juni 2025 eine bedeutende Gew盲hrung von Aktienoptionen. Die Transaktion mit derivativen Wertpapieren umfasste:

  • Gew盲hrung von 637.500 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 7,43 $ pro Aktie
  • Optionen laufen am 19. Juni 2035 ab
  • Vesting-Plan: 1/48 der Aktien werden monatlich ab dem 20. Juni 2025 freigegeben

Diese Form-4-Meldung legt die aktienbasierte Verg眉tung f眉r Wong offen, der sowohl Direktor als auch CEO ist. Die umfangreiche Optionsgew盲hrung, die direkten Eigentumserwerb darstellt, scheint Teil der Verg眉tungsstrategie des Unternehmens zu sein, um die Interessen des Managements langfristig 眉ber einen Zeitraum von zehn Jahren mit denen der Aktion盲re in Einklang zu bringen.

Positive
  • CEO Brian Russell Wong granted 637,500 stock options with 4-year monthly vesting schedule, aligning long-term interests with shareholders
Negative
  • None.

Brian Russell Wong, Presidente e CEO di RAPT Therapeutics, ha ricevuto una significativa concessione di opzioni su azioni il 20 giugno 2025. La transazione relativa a strumenti derivati comprendeva:

  • Concessione di 637.500 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Scadenza delle opzioni il 19 giugno 2035
  • Piano di maturazione: 1/48 delle azioni matura mensilmente a partire dal 20 giugno 2025

Questo deposito del Modulo 4 rende nota la concessione di compensi azionari a Wong, che ricopre sia il ruolo di Direttore che di CEO. La consistente assegnazione di opzioni, che rappresenta una propriet脿 diretta, sembra far parte della strategia di remunerazione esecutiva dell'azienda per allineare gli interessi del management con quelli degli azionisti in un periodo di lungo termine di dieci anni.

Brian Russell Wong, Presidente y CEO de RAPT Therapeutics, recibi贸 una importante concesi贸n de opciones sobre acciones el 20 de junio de 2025. La transacci贸n con valores derivados incluy贸:

  • Concesi贸n de 637,500 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $7.43 por acci贸n
  • Las opciones expiran el 19 de junio de 2035
  • Calendario de adquisici贸n: 1/48 de las acciones se adquiere mensualmente a partir del 20 de junio de 2025

Esta presentaci贸n del Formulario 4 revela la concesi贸n de compensaci贸n basada en acciones a Wong, quien es Director y CEO. La considerable concesi贸n de opciones, que representa propiedad directa, parece ser parte de la estrategia de compensaci贸n ejecutiva de la compa帽铆a para alinear los intereses de la gerencia con los de los accionistas durante un per铆odo a largo plazo de diez a帽os.

RAPT Therapeutics鞚� 靷灔 瓴� CEO鞚� Brian Russell Wong鞚� 2025雲� 6鞗� 20鞚检棎 靸侂嫻頃� 欤检嫕毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃姷雼堧嫟. 鞚� 韺岇儩靸來拡 瓯半灅電� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 甑Г頃� 靾� 鞛堧姅 637,500 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $7.43搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 19鞚�
  • 氩犾姢韺� 鞚检爼: 2025雲� 6鞗� 20鞚茧秬韯� 毵れ洈 1/48鞌� 氩犾姢韺�

鞚� Form 4 鞝滌稖靹滊姅 鞚挫偓鞚挫瀽 CEO鞚� Wong鞐愱矊 歆�旮夒悳 欤检嫕 旮半皹 氤挫儊 攵赌鞐ゼ 瓿店皽頃╇媹雼�. 歆侅爲 靻岇湢甓岇潉 雮橅儉雮措姅 靸侂嫻頃� 鞓奠厴 攵赌鞐姅 瓴届榿歆勳潣 鞚挫澋鞚� 欤检＜鞕� 鞛リ赴鞝侅溂搿� 10雲� 霃欖晥 鞚检箻鞁滍偆旮� 鞙勴暅 須岇偓鞚� 鞛勳洂 氤挫儊 鞝勲灥鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟.

Brian Russell Wong, Pr茅sident et CEO de RAPT Therapeutics, a re莽u une attribution importante d鈥檕ptions d鈥檃chat d鈥檃ctions le 20 juin 2025. La transaction concernant des titres d茅riv茅s comprenait :

  • Attribution de 637 500 options d鈥檃chat d鈥檃ctions pour acqu茅rir des actions ordinaires
  • Prix d鈥檈xercice fix茅 脿 7,43 $ par action
  • Expiration des options le 19 juin 2035
  • Calendrier d鈥檃cquisition : 1/48 des actions acquises chaque mois 脿 partir du 20 juin 2025

Ce d茅p么t du formulaire 4 r茅v猫le l鈥檃ttribution de r茅mun茅ration en actions 脿 Wong, qui est 脿 la fois administrateur et CEO. Cette importante attribution d鈥檕ptions, repr茅sentant une propri茅t茅 directe, semble faire partie de la strat茅gie de r茅mun茅ration des dirigeants de l鈥檈ntreprise visant 脿 aligner les int茅r锚ts de la direction avec ceux des actionnaires sur une p茅riode longue de dix ans.

Brian Russell Wong, Pr盲sident und CEO von RAPT Therapeutics, erhielt am 20. Juni 2025 eine bedeutende Gew盲hrung von Aktienoptionen. Die Transaktion mit derivativen Wertpapieren umfasste:

  • Gew盲hrung von 637.500 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 7,43 $ pro Aktie
  • Optionen laufen am 19. Juni 2035 ab
  • Vesting-Plan: 1/48 der Aktien werden monatlich ab dem 20. Juni 2025 freigegeben

Diese Form-4-Meldung legt die aktienbasierte Verg眉tung f眉r Wong offen, der sowohl Direktor als auch CEO ist. Die umfangreiche Optionsgew盲hrung, die direkten Eigentumserwerb darstellt, scheint Teil der Verg眉tungsstrategie des Unternehmens zu sein, um die Interessen des Managements langfristig 眉ber einen Zeitraum von zehn Jahren mit denen der Aktion盲re in Einklang zu bringen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wong Brian Russell
(Last) (First) (Middle)
C/O RAPT THERAPEUTICS, INC.
561 ECCLES AVENUE
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $7.43 06/20/2025 A 637,500 (1) 06/19/2035 Common Stock 637,500 $0 637,500 D
Explanation of Responses:
1. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.
/s/ Rodney Young, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many stock options did RAPT Therapeutics CEO Brian Wong receive on June 20, 2025?

RAPT Therapeutics CEO Brian Wong received 637,500 employee stock options on June 20, 2025, with an exercise price of $7.43 per share.

What is the vesting schedule for RAPT CEO's June 2025 stock option grant?

The stock options vest monthly over 4 years, with 1/48th of the shares vesting each month starting from the vesting commencement date of June 20, 2025.

When do Brian Wong's RAPT stock options expire?

The stock options granted to Brian Wong expire on June 19, 2035, ten years from the grant date.

What positions does Brian Wong hold at RAPT Therapeutics?

Brian Wong serves as both the President and CEO of RAPT Therapeutics, as well as a Director on the company's board.

What was the exercise price of RAPT CEO's June 2025 stock option grant?

The exercise price (conversion price) of the stock options granted to CEO Brian Wong was $7.43 per share.
Stock RAPT logo
Rapt Therapeutics, Inc.

NASDAQ:RAPT

RAPT Rankings

#6028 Ranked by Market Cap
N/A Ranked by Dividends

RAPT Latest News

Jun 23, 2025
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
Jun 13, 2025
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
Jun 4, 2025
RAPT Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2025
RAPT Therapeutics Reports First Quarter 2025 Financial Results
Apr 15, 2025
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of聽Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Latest SEC Filings

Jun 30, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Jun 30, 2025
[Form 3] RAPT Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jun 24, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Jun 24, 2025
[Form 3] RAPT Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jun 24, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

RAPT Stock Data

135.93M
12.71M
0.49%
96.43%
1.99%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO